1
ALL1
Dr. Reddy's LaboratoriesYear
1
ALL1
2021DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
INDIA1
ALL1
InapplicableTherapeutic Area
1
ALL1
Infections and Infectious DiseasesStudy Phase
1
ALL1
Approved FDFDeal Type
1
ALL1
InapplicableProduct Type
1
ALL1
Other Small MoleculeDosage Form
1
ALL1
InjectionLead Product
1
ALL1
Ertapenem SodiumTarget
1
ALL1
PBPLead Product(s) : Ertapenem Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market
Details : Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Ertapenem Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable